Mundipharma Ties up with Samsung Bioephis to Expand Biosimilars into Hong Kong and Taiwan

Mundipharma, a global network of independent associated companies covering the world’s pharmaceutical markets, enters into partnership with Samsung Biosephis to commercialize Samsung Bioepsis’s first wave biosimilar candidates in Taiwan and Hong Kong. The company has a significant presence in the field of pain medicine and growing presence in three other core therapeutic areas of respiratory, oncology and biosimilars the world over.

Mundipharma strives to deliver consistently high quality products while standing up with the mission to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Samsung bioepis is a joint venture between Samsung Biologics and Biogen and commits to realizing healthcare that is accessible to everyone through innovations in product development and a firm commitment to quality. It continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology,

This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments

oncology, ophthalmology and hematology.

The partnership between Mundipharma and Samsung Bioepsis covers Samsung Bioepis' biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).

The partnership makes Mundipharma the exclusive commercialization partner, while Samsung Bioepis remains as the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.

"This partnership brings together Samsung Bioepis' proven biosimilar development platform with Mundipharma's commercial acumen and market insight and ability to increase patient access to proven treatments," says Mundipharma CEO, Raman Singh. "This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments," he adds.